Lundgren JD, Grund B, Barkauskas CE, et al. - Among patients who were hospitalized with coronavirus disease 2019 (COVID-19), this inquiry was conducted to determine the impact of a neutralizing monoclonal antibody (LY-CoV555) in this patient group. Participants included hospitalized patients who had COVID-19 without end-organ failure; these patients were randomized in a 1:1 ratio to receive either LY-CoV555 or matching placebo. Also, high-quality supportive care was given to all patients as a background therapy, including the antiviral drug remdesivir and, when indicated, supplemental oxygen and glucocorticoids were provided. A sustained recovery during a 90-day period, as evaluated in a time-to-event analysis, was the primary outcome. Findings revealed that in hospitalized patients who had COVID-19 without end-organ failure, no effectiveness was shown by monoclonal antibody LY-CoV555 when coadministered with remdesivir. In the LY-CoV555 group and the placebo group, the percentage of patients with the primary safety outcome (a composite of death, serious adverse events, or clinical grade 3 or 4 adverse events through day 5) was comparable.